Palo Alto Investors’s Relmada Therapeutics RLMD Stock Holding History

Palo Alto Investors’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-495,146	Closed	-$134K	–	46
2025 Q1	$134K	Hold	495,146	–	–	0.03%	43
2024 Q4	$257K	Sell	495,146 -237,254	-32%	-$579K	0.04%	40
2024 Q3	$2.37M	Hold	732,400	–	–	0.31%	29
2024 Q2	$2.2M	Hold	732,400	–	–	0.25%	30
2024 Q1	$3.41M	Hold	732,400	–	–	0.38%	28
2023 Q4	$3.03M	Hold	732,400	–	–	0.27%	26
2023 Q3	$2.2M	Hold	732,400	–	–	0.21%	22
2023 Q2	$1.8M	Buy	732,400 +190,300	+35%	+$526K	0.15%	24
2023 Q1	$1.23M	Buy	+542,100	New	+$1.87M	0.1%	27

Other funds holding RLMD

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

Palo Alto Investors's RLMD Position: Q2 2025 in Review

Palo Alto Investors sold out of Relmada Therapeutics (RLMD) in Q2 2025, closing a stake of 495,146 shares — an estimated $134K sold.

Palo Alto Investors first reported a position in RLMD in Q1 2023 and held it in 9 quarters. The position peaked at $3.41M in Q1 2024. 50 funds tracked by Wall St. Rank hold RLMD as of Q2 2025.

Palo Alto Investors reported no remaining Relmada Therapeutics position as of Q2 2025 after selling out during the quarter.
Palo Alto Investors sold 495,146 Relmada Therapeutics shares in Q2 2025, an estimated $134K.
Palo Alto Investors first reported a position in Relmada Therapeutics in Q1 2023 and held it in 9 quarters.
Palo Alto Investors's Relmada Therapeutics position peaked at $3.41M in Q1 2024.
50 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2025.

Based on Palo Alto Investors's 13F filing for Q2 2025, filed 14 Aug 2025.